Novo Nordisk NVO announced Monday that its oral GLP-1 called Rybelsus wasn’t better than a placebo at delaying the progression of Alzheimer’s disease. It shared few details beyond saying the ...

Vascular dementia is a decline in memory, thinking skills, and self-care that occurs due to strokes in the areas of the brain ...

Alzheimer's disease is a type of dementia, but not all dementia is Alzheimer's. Dementia symptoms include memory loss, problem-solving trouble, and trouble completing tasks. Seeking early diagnosis ...

Mixed dementia, also known as multifactorial dementia, is when you have brain changes from two or more types of dementia at the same time. In mild cognitive decline, you may have trouble remembering ...

"Exciting" new research suggests a supplement could potentially lower the risk of Alzheimer's disease. The study found that ...

An older oral version of the company's semaglutide drug failed to meet its main goal in late-stage trials testing whether the ...

Studies from Novo Nordisk due early next month will give the strongest indication yet of whether blockbuster GLP-1 drugs - a ...

New research has established a link between a specific type of body fat and the brain proteins that are hallmarks of Alzheimer’s disease. The type of fat is especially common for people in middle age ...

Type 1 diabetes was linked to increased risk for dementia, especially vascular dementia, non-Alzheimer-nonvascular dementia, and Alzheimer disease.

Type 2 diabetes is a serious and fast-growing global health burden that contributes not only to physical complications, but ...